| Neuroblastoma
Danyelza vs Unituxin
Side-by-side clinical, coverage, and cost comparison for neuroblastoma.Deep comparison between: Danyelza vs Unituxin with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUnituxin has a higher rate of injection site reactions vs Danyelza based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Unituxin but not Danyelza, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Danyelza
Unituxin
At A Glance
IV infusion
Every 4-8 weeks
Anti-GD2 monoclonal antibody
IV infusion
4 consecutive days per cycle
Anti-GD2 monoclonal antibody
Indications
- Neuroblastoma
- Neuroblastoma
Dosing
Neuroblastoma 3 mg/kg/day (up to 150 mg/day) IV infusion on Days 1, 3, and 5 of each 4-week cycle in combination with GM-CSF; cycles repeated every 4 weeks until complete or partial response, followed by 5 additional cycles every 4 weeks; subsequent cycles may be repeated every 8 weeks.
Neuroblastoma 17.5 mg/m2/day as an intravenous infusion over 10 to 20 hours for 4 consecutive days per cycle for a maximum of 5 cycles; initiate at 0.875 mg/m2/hour and titrate to a maximum rate of 1.75 mg/m2/hour.
Contraindications
- History of severe hypersensitivity reaction (including anaphylaxis) to naxitamab-gqgk
- History of anaphylaxis to dinutuximab
Adverse Reactions
Most common (>=25%) Infusion-related reaction, pain, tachycardia, vomiting, cough, nausea, diarrhea, decreased appetite, hypertension, fatigue, erythema multiforme, peripheral neuropathy, urticaria, pyrexia, headache, injection site reaction, edema, anxiety, localized edema, irritability
Serious Infusion-related reactions (including anaphylaxis), neurotoxicity, myocarditis, hypertension, orthostatic hypotension
Postmarketing Orthostatic hypotension, transverse myelitis, myocarditis
Most common (>=25%) Pain, pyrexia, thrombocytopenia, lymphopenia, infusion reactions, hypotension, hyponatremia, increased alanine aminotransferase, anemia, vomiting, diarrhea, hypokalemia, capillary leak syndrome, neutropenia, urticaria, hypoalbuminemia, increased aspartate aminotransferase, hypocalcemia
Serious Infections, infusion reactions, hypokalemia, hypotension, pain, fever, capillary leak syndrome
Postmarketing Prolonged urinary retention, transverse myelitis, reversible posterior leukoencephalopathy syndrome (RPLS)
Pharmacology
Naxitamab-gqgk is a humanized IgG1 monoclonal antibody that binds to GD2, a disialoganglioside overexpressed on neuroblastoma cells and other cells of neuroectodermal origin, inducing complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).
Anti-GD2 chimeric monoclonal antibody that binds to cell surface GD2 expressed on neuroblastoma cells and induces cell lysis through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Danyelza
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Unituxin
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Danyelza
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Unituxin
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Danyelza
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Unituxin
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availablePAF Co-Pay Relief: Brain Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availablePAF Co-Pay Relief: Brain Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DanyelzaView full Danyelza profile
UnituxinView full Unituxin profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.